Reversible stencils for fabricating micro-tissues
The invention relates to devices, methods, kits, and compositions for in vitro generation of three-dimensional micro-tissues that are accurate models of heart, skeletal muscle, neuronal, and other tissues.
1. A method of inducing self-assembly of mammalian cells into one or more dog-bone shaped micro-tissues comprising
seeding the mammalian cells into one or more microwells of a device comprising
a cell adhesion substrate; and
a removable elastomeric stencil overlay comprising one or more cut-out patterned microwells comprising two or more circular, oval, rectangular, square, V-shaped, or triangular holes, each hole joined to an adjacent hole by a canal; and
culturing the seeded cells within the microwells, to thereby induce self-assembly of the mammalian cells into one or more dog-bone micro-tissues shaped within adjacent holes and along the canal joining the adjacent holes;
wherein the cell adhesion substrate binds cells within at least the holes of the cut-out pattern.
2. The method of claim 1 , wherein about 2000 to about 9500 cells are seeded into each of several microwells of the device.
3. The method of claim 1 , wherein each of the microwells has a depth of at least 250 μm or at least 500 μm.
4. The method of claim 1 , wherein at least one of the microwells has at least two square holes with a side length “L” of 250 μm to 1000 μm, and the canal joining the two square holes has a longitudinal length “X” of 250-1000 μm a transverse width “Y” of 50-200μm.
5. The method of claim 1 , wherein the ratio of L to Y is at least five.
6. The method of claim 1 , wherein the seeded cells are a mixture of mammalian cell types typically present in a mammalian organ.
7. The method of claim 6 , wherein the mammalian organ is selected from the group consisting of heart, muscle, and neuronal tissue.
8. The method of claim 1 , wherein the mammalian cells comprise a heterologous marker gene, a heterologous reporter gene, a mutant gene, or a combination thereof.
9. The method of claim 1 , wherein the mammalian cells comprise a marker gene encodes a fluorescent protein.
10. The method of claim 1 , wherein the mammalian cells comprise a mutation in any of the following genes: ABCC9, ACTC1, ACTN2, ANKRD1, AKAP9, ANK2, BAG3, CACNA1C, CACNB2, CASQ2, CAV3, COX15, CRYAB, CSRP3, CTF1, DES, DMD, DNAJC19, DSC2, DSG2, DSP, DTNA, EYA4, FHL2, FKTN, FOXD4, GLA, KCNE1, KCNE2, KCNH2, KCNJ5, KCNJ8, KCNQ1, KCNQ2, LAMA4, LAMP2, LDB3, LMNA, MYBPC3, MYH6, MYH7, MYL2, MYL3, MYOZ2, NEXN, PKP2, PLN, PRKAG2, PSEN1, PSEN2, RBM20, RYR2, SCN5A, SDHA, SGCD, SNTA1, SYNE1, SYNE2, TAZ, TCAP, TMEM43, TMPO, TNNC1, TNNT2, TNNC1, TNNI3, TPM1, TRDN, TTN, TTR, VCL, or any combination thereof.
11. The method of claim 1 , wherein seeding the mammalian cells comprises settling the cells into the microwells by gravity or by fluid flow through a membrane at the bottom of the microwells.
12. The method of claim 1 , further comprising introducing a test compound, oligonucleotide, nucleic acid, protein, or a combination thereof into one or more microwells while culturing the seeded cells within the microwells.
13. The method of claim 1 , further comprising introducing a test compound, oligonucleotide, nucleic acid, protein, or a combination thereof into one or more microwells via membrane at the bottom of the microwells, where the microwells are operably connected to a network of microfluidic channels for introduction of the test compound, oligonucleotide, nucleic acid, protein, or a combination thereof.
14. The method of claim 1 , further comprising determining whether cells are aligned in one or more canals of one or more of the microwells.
15. The method of claim 1 , further comprising determining whether cells have formed dog-bone shaped structures in one or more canals or holes of the microwells.
16. The method of claim 1 , further comprising determining whether cells are contracting along the longitudinal axis of one or more of the microwells.
17. The method of claim 1 , further comprising culturing one or more micro-tissues in a medium containing a test agent.
18. The method of claim 1 , further comprising determining micro-tissue morphology, genetic expression, contraction rate, contraction intensity, electrical activity, calcium transient amplitude, intracellular Ca 2+ level, cell size contractile force production, sarcomeric α-actinin distribution, or a combination thereof.
19. The method of claim 1 , wherein cells within the micro-tissues formed in the microwells exhibit contractility with greater synchronicity than two-dimensional monolayers of the same cell type and composition.
20. The method of claim 1 , wherein cells within the micro-tissues formed in the microwells respond to drugs with greater synchronicity than two-dimensional monolayers of the same cell type and composition.
21. The method of claim 1 , wherein cells within the micro-tissues formed in the microwells exhibit more synchronized chronotropic and/or inotropic responses to drugs compared to than two-dimensional monolayers of the same cell type and composition.
22. The method of claim 1 , further comprising removing the stencil to generate intact micro-tissues.
23. The method of claim 1 , further comprising recovering cells from the microwells and determining expression of one or more mRNA or protein.
24. The method of claim 1 , further comprising immersing one or more micro-tissues in a support medium, damaging one or more micro-tissues, embedding one or more micro-tissues, fixing one or more micro-tissues, fixing one or more micro-tissues, freezing one or more micro-tissues, sectioning one or more micro-tissues, staining one or more micro-tissues, or a combination thereof.
25. The method of claim 1 , wherein the mammalian cells seeded in the microwells are wild type or mutant somatic cells converted into induced pluripotent stem cells and then differentiated into a desired lineage.